canertinib has been researched along with zm 447439 in 2 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (zm 447439) | Trials (zm 447439) | Recent Studies (post-2010) (zm 447439) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 25 | 0 | 17 |
| Protein | Taxonomy | canertinib (IC50) | zm 447439 (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 0.1315 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.11 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.039 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.039 | |
| Aurora kinase A | Mus musculus (house mouse) | 0.039 | |
| Aurora kinase B-A | Xenopus laevis (African clawed frog) | 0.045 | |
| Aurora kinase B | Homo sapiens (human) | 0.1213 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, D; Hong, J | 1 |
| Bansal, R; Malhotra, A | 1 |
2 review(s) available for canertinib and zm 447439
| Article | Year |
|---|---|
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |